Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer - A time for excitement and equipoise

被引：19

作者：

Azzoli, Christopher G. ^{[1
]}

Park, Bernard J. ^{[2
]}

Pao, William ^{[1
]}

Zakowski, Maureen ^{[3
]}

Kris, Mark G. ^{[1
]}

机构：

[1] Cornell Univ, Dept Med, Thorac Oncol Serv,Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol,Weill Med Coll, New York, NY 10021 USA

[2] Cornell Univ, Dept Surg, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[3] Cornell Univ, Dept Pathol, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2008年 / 3卷 / 01期

关键词：

non-small cell lung cancer; adjuvant chemotherapy; molecular markers; biomarkers; KRAS (Kirsten rat sarcoma viral oncogene homolog); EGFR (epidermal growth factor receptor); ERCC1 (excision repair cross-complementation group 1); p27(Kip1); MRP2 (multidrug resistance protein 2); bTubIII (class III beta-tubulin);

D O I：

10.1097/JTO.0b013e31815efe24

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In patients with previously-untreated, completely-resected pathologic stage II-III non-small cell lung cancer, 4 months of postoperative cisplatin-based chemotherapy reduces the risk of death by approximately 20%. To date, the only prospectively validated prognostic and predictive factor which can be used to guide clinical practice is pathologic stage. Higher stage patients have a worse prognosis, but derive more benefit from adjuvant chemotherapy. Numerous molecular markers are being developed with the potential to help decide which patients to treat with adjuvant chemotherapy, and which drugs to use. This paper will review the molecular markers which are having immediate impact on treatment decisions in routine practice, and which merit further study in the next generation of adjuvant chemotherapy trials.

引用

页码：84 / 93

页数：10

共 78 条

[21] Noise and bias in microarray analysis of tumor specimens [J].

Febbo, Phillip G. ;

Kantoff, Philip W. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (23) :3719-3721

[22] Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer:: The international adjuvant lung cancer trial biologic program [J].

Filipits, Martin ;

Pirker, Robert ;

Dunant, Ariane ;

Lantuejoul, Sylvie ;

Schmid, Katharina ;

Huynh, Anh ;

Haddad, Vincent ;

Andre, Fabrice ;

Stahel, Rolf ;

Pignon, Jean-Pierre ;

Soria, Jean-Charles ;

Popper, Helmut H. ;

Le Chevalier, Thierry ;

Brambilla, Elisabeth .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :2735-2740

[23] Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program [J].

Filipits, Martin ;

Haddad, Vincent ;

Schmid, Katharina ;

Huynh, Anh ;

Dunant, Ariane ;

Andre, Fabrice ;

Brambilla, Elisabeth ;

Stahel, Rolf ;

Pignon, Jean-Pierre ;

Soria, Jean-Charles ;

Popper, Helmut H. ;

Le Chevalier, Thierry ;

Pirker, Robert .

CLINICAL CANCER RESEARCH, 2007, 13 (13) :3892-3898

[24] Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers [J].

Grossi, F ;

Loprevite, M ;

Chiaramondia, M ;

Ceppa, P ;

Pera, C ;

Ratto, GB ;

Serrano, J ;

Ferrara, GB ;

Costa, R ;

Boni, L ;

Ardizzoni, A .

EUROPEAN JOURNAL OF CANCER, 2003, 39 (09) :1242-1250

[25] Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma [J].

Guo, Lan ;

Ma, Yan ;

Ward, Rebecca ;

Castranova, Vince ;

Shi, Xianglin ;

Qian, Yong .

CLINICAL CANCER RESEARCH, 2006, 12 (11) :3344-3354

[26] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

[27] Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers:: Analysis in combination with expressions of p16INK4A, pRB, and p53 [J].

Hirabayashi, H ;

Ohta, M ;

Tanaka, H ;

Sakaguchi, M ;

Fujii, Y ;

Miyoshi, S ;

Matsuda, H .

JOURNAL OF SURGICAL ONCOLOGY, 2002, 81 (04) :177-184

[28] Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib [J].

Hirsch, F. R. ;

Varella-Garcia, M. ;

Cappuzzo, F. ;

McCoy, J. ;

Bemis, L. ;

Xavier, A. C. ;

Dziadziuszko, R. ;

Gumerlock, P. ;

Chansky, K. ;

West, H. ;

Gazdar, A. F. ;

Crino, L. ;

Gandara, D. R. ;

Franklin, W. A. ;

Bunn, P. A., Jr. .

ANNALS OF ONCOLOGY, 2007, 18 (04) :752-760

[29] Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis [J].

Hirsch, FR ;

Varella-Garcia, M ;

Bunn, PA ;

Di Maria, MV ;

Veve, R ;

Bremnes, RM ;

Barón, AE ;

Zeng, C ;

Franklin, WA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) :3798-3807

[30] K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer:: a combined analysis of 881 cases [J].

Huncharek, M ;

Muscat, J ;

Geschwind, JF .

CARCINOGENESIS, 1999, 20 (08) :1507-1510

← 1 2 3 4 5 6 7 8 →